Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06285370 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

StatusActive, Not Recruiting
PhasePhase 4
Started2023-05-29
View on ClinicalTrials.gov ↗
The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy

Amendment record

Amended 2 times since 2024-02-27; most recent filed 2025-09-17. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2025-09-17
Amendment Recruiting→Active, Not Recruiting Study Status, Study Design, Eligibility, Contacts/Locations v2
2024-04-26
Amendment Study Identification, Study Status v1
2024-02-27
Original filing
Trial Details
NCT Number NCT06285370
Lead Sponsor Kyowa Kirin China Pharmaceutical Co., Ltd.
Conditions Cutaneous T-Cell Lymphoma
Enrollment 23 participants
Start Date 2023-05-29
Primary Completion 2025-08-12 (estimated)
Study Completion 2025-11-13 (estimated)
Updated on ClinicalTrials.gov 2025-09-18